Pharmaceutical News and Articles

Alto Neuroscience Reports Topline Results from a Phase 2b Trial Evaluating ALTO-100 as a Treatment for Major Depressive Disorder

Alto Neuroscience, Inc. ( Alto ) (NYSE ANRO), a clinical stage biopharmaceutical company focused on the development of novel precision medicines for neuropsychi

NIH Clinical Trial Will Test Precision Medicine Treatments for Myeloid Cancers

The National Institutes of Health (NIH) has launched a proof-of-concept precision medicine clinical trial to test new treatment combinations targeting specific

Avadel Pharmaceuticals Announces FDA Approval of Lumryz (sodium oxybate) Extended-Release Oral Suspension (CIII) for the Treatment of Cataplexy or Excessive Daytime Sleepiness in Patients 7 Years of Age and Older with Narcolepsy

Poor Cardiovascular Health Linked to Composite of Poor Brain Health

Poor cardiovascular health profiles, captured by the American Heart Association Life s Essential 8 (LE8), are associated with an increased risk for developing a

Balancing on One Leg Is Most Reliable Measure of Neuromuscular Aging

Duration of one-legged balance is the most reliable measure of neuromuscular aging for both older men and women, according to a study published online Oct. 23 i

Risk for Psychiatric Disorders Up for Offspring of Moms With Eating Disorder

Offspring of mothers with an eating disorder or prepregnancy body mass index (BMI) outside the normal weight range have an increased risk for psychiatric disord

Adult Hypertension Prevalence 47.7 Percent From August 2021 to August 2023

During August 2021 to August 2023, the prevalence of adult hypertension was 47.7 percent, with hypertension higher in men than women, according to an October da

Poor Sleep Quality Linked to Older Brain Age in Late Midlife

Poor sleep quality is associated with advanced brain age in midlife, according to a study published online Oct. 23 in Neurology.Cl mence Cavailles, Ph.D., from

FDA Approves Vyloy for Advanced Gastric or Gastroesophageal Junction Cancer

The U.S. Food and Drug Administration has approved Vyloy (zolbetuximab-clzb) in combination with fluoropyrimidine- and platinum-containing chemotherapy for the

Exposure to Inorganic Arsenic in Drinking Water Increases Cardiovascular Risk

Long-term exposure to inorganic arsenic in drinking water (wAs) from U.S. community water supplies (CWS) at levels below the federal maximum contaminant level o